ClinicalTrials.gg
TerminatedNCT03355300Updated Jun 18, 2023Results posted

Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

A Phase 2 interventional study of Cannabidiol Oral Solution in Childhood Absence Epilepsy, sponsored by Radius Pharmaceuticals, Inc.. Terminated at 9 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Radius Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Insys Therapeutics filed Chapter 11 and terminated all studies.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Epilepsy, Absence with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Epilepsy, Absence · United States.

Enrollment
11th of 11
11 · median 40
Started
2018
the only one that year
Phase 2
3 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
2 of 16
Radius Pharmaceuticals, Inc.

Among the 16 studies in Epilepsy, Absence with a site in United States, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 3 in phase 2, and was the 6th registered.

Epilepsy, Absence

24 studies on the registry are indexed under Epilepsy, Absence; 2 are open to participants now.

Browse Epilepsy, Absence studies →

Open to participants now

1 of the 16 studies in Epilepsy, Absence with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Epilepsy, Absence studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Epilepsy, Absence with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in pediatric participants with treatment-resistant childhood absence seizures.

03

Conditions studied

  • Childhood Absence Epilepsy

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed all activities through Visit 6 (End of Study) of INS011-17-103.
  2. Participant and/or parent(s)/caregiver(s) fully comprehend the form (ICF) and assent form, understand all study procedures, and can communicate satisfactorily with the investigator and study coordinator, in accordance with applicable laws, regulations, and local requirements.
  3. A female participant is eligible to participate in the study if she is premenarchal, or of with a negative urine pregnancy test at the Screening Visit. If sexually active, she must agree to either complete abstinence from intercourse or use acceptable methods of throughout the study and for 4 weeks after completion of study participation or discontinuation from product.
  4. A sexually active male participant or partner of enrolled participant must be willing to use acceptable methods of contraception throughout the study and for 4 weeks after completion of study participation or discontinuation from investigational product.
  5. In the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and able to comply with the study procedures and visit schedules, including venipuncture, and the visit schedules.

Exclusion criteria

Exclusion Criteria:

  1. Participant or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits.
  2. Experienced an anoxic episode related to study drug requiring resuscitation during their previous study.
  3. Developed an adverse event thought to be related to CBD in the previous study and for whom the Investigator determines that continuing treatment with CBD would not be in the best interest of the participant.
  4. Evidence of other disease such as unstable hepatic, hematological, renal, cardiovascular, gastrointestinal, immunological, or pulmonary diseases or ongoing .
  5. Compromised respiratory function or severe respiratory insufficiency.
  6. Clinically significant abnormal laboratory values within the past 14 days.
  7. In the opinion of the investigator, the participant is unsuitable in any other way to participate in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Cannabidiol Oral Solution

    Cannabidiol Oral solution, dose as assigned in INS-17-103.

    Drug: Cannabidiol Oral Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported AEs module.

    Time frame: Baseline (Visit 6 of INS011-17-103) and Visit 10 (up to approximately 54 weeks)

07

Results

Posted Jun 18, 2023
Limitations and caveats
This study was prematurely terminated by the Sponsor. Participants ongoing at the time of discontinuation of the study are neither considered completed or discontinued.

Participant flow

Participant flow — Overall Study
MilestoneCanabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/Day
Started56
Completed24
Not completed32
Withdrew: Physician decision01
Withdrew: Lack of efficacy21
Withdrew: Other reason10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported AEs module.

Time frame:
Baseline (Visit 6 of INS011-17-103) and Visit 10 (up to approximately 54 weeks)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsCanabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/Day
Number of participants with AEs54
Number of participants with SAEs00

Adverse events

Collected over Baseline (Visit 6 of INS011-17-103) and Visit 10 (up to approximately 54 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Canabidiol Oral Solution 20 to <30 mg/kg/Day0/5 (0%)0/5 (0%)4/5 (80%)
Canabidiol Oral Solution 30 to <40 mg/kg/Day0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCanabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/Day
PyrexiaGeneral disorders1/50/6
Seasonal allergyImmune system disorders1/50/6
Coordination abnormalNervous system disorders1/50/6
HeadacheNervous system disorders1/50/6
SeizureNervous system disorders1/50/6
SomnolenceNervous system disorders1/50/6
HallucinationPsychiatric disorders1/50/6
VomitingGastrointestinal disorders0/51/6
FatigueGeneral disorders0/51/6
Pharyngitis streptococcalInfections and infestations0/51/6

Baseline characteristics

All participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Canabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/DayTotal
Mean8.4 ± 2.4110.7 ± 3.019.6 ± 2.87
Sex: Female, Male
Sex: Female, Male(Participants)Canabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/DayTotal
Female426
Male145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Canabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/DayTotal
Hispanic or Latino000
Not Hispanic or Latino5611
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Canabidiol Oral Solution 20 to <30 mg/kg/DayCanabidiol Oral Solution 30 to <40 mg/kg/DayTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5611
More than one race000
Unknown or Not Reported000
08

Study locations

9 sites
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Pediatric Epilepsy and Neurology Specialists
    Tampa, Florida 33609, United States
  • Clinical Integrative Research Center of Atlanta
    Atlanta, Georgia 30328, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Children's Specialty Group, Division of Child & Adolescent Neurology
    Norfolk, Virginia 23510, United States
  • Institute for Research and Innovation | MultiCare Health System
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jun 2019, 16 months.

Results were first posted in Jun 2023, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 28, 2017
StartActual
Feb 20, 2018
Primary completionActual
Jun 24, 2019
CompletionActual
Jun 28, 2019
Results first posted
Jun 18, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03355300
Lead sponsor
Radius Pharmaceuticals, Inc.
Collaborators
Benuvia Therapeutics Inc.
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Feb 20, 2018
Primary completion
Jun 24, 2019
Completion
Jun 28, 2019
Results posted
Jun 18, 2023
Last update
Jun 18, 2023

Study contacts

Ahmed Elkashef, MD
study director · INSYS Therapeutics Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion